Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 3, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 1, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$64.54 – $66.49Entry zone — fair-value band

$69.04Published — price the day we called it

$81.93Target — the price the thesis aimed for

$71.00Peak — highest point inside the window, not a realized return

$59.17Window close — end-of-window price, context only

What happened

Partial

Reached 14% of the predicted growth at its peak, without hitting the target.

Peak price

$71.00

peak on July 25, 2025 — not a realized return

Peak gain

+2.8%

peak, from the publication price

Window close

$59.17

end-of-window price, context only

Days to target

—

Window

July 3, 2025 – October 1, 2025

The thesis — published July 3, 2025

Predicted growth

+20%

over the measurement window

Target price

$81.93

the price the thesis aimed for

Entry zone

$64.54 – $66.49

the fair-value band we waited for

Price at publication

$69.04

published July 3, 2025

Confidence

85%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Demand for semaglutide, Novo's key weight-loss drug, keeps rising fast. A July 2 study now sees the potential customer base for obesity medicines topping $61 billion by 2033. After the share price fell 12 percent, many indicators show sellers may be finished while the business stays healthy. New factory space in Denmark and North Carolina plus final trial results for a follow-up drug could lift the stock back toward recent highs within three months.

Primary drivers

Semaglutide sales grow over 25 percent yearly, and weight-loss demand may soon pass diabetes.
July 2 report puts potential customer base at $61 billion, confirming solid long-term demand.
Factories opening this fall should ease shortages and let Novo ship more drugs later in 2024.
Price looks beaten down, and recent heavy buying hints the stock could bounce soon.

How it played out

NVO: target was not reached

Lyra published NVO at 69.04 on 2025-07-03 with a short-term 20 percent expected gain. The thesis pointed to semaglutide demand, a $61 billion potential customer base, new factory space in Denmark and North Carolina, final trial results for a follow-up drug, and a beaten-down price after a 12 percent fall.

Inside the 2025-07-03 to 2025-10-01 window, NVO peaked at 71 on 2025-07-25, a 2.8 percent gain. It stayed below the 81.93 target and never reached it. The stock ended at 59.17. The thesis missed.

What happened during the window

On 2025-08-06, Novo Nordisk reported first-half sales of 155 billion Danish kroner, with obesity drug sales up 56 percent. On 2025-09-10, the company announced a restructuring with 9,000 job cuts and a lower 2025 profit forecast.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals